RRAS2 and breast cancer: With some differences in specific phosphorylation sites, the effect of R-RAS2 depletion in the human BT-549 breast cancer cell line also involved depressing the activity of the Raf/ERK, PI3K/Akt, and mTOR pathways (Suppl.